Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. News
  7. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AbbVie Eye Drug AGN-190584 Meets Endpoints in Phase 3 Study

07/26/2021 | 06:34am EDT

By Matt Grossman

AbbVie Inc.'s AGN-190584 drug, a potential treatment for presbyopia, met the primary and secondary endpoints of a Phase 3 trial, the company said Sunday.

If approved the drug would be the first eye-drop treatment for presbyopia, an inability to focus on near objects, AbbVie said. In the trial, AGN-190584 had a rapid onset of action and vision improved for up to six hours. There was no loss of distance vision, AbbVie said.

The study included 323 participants, half of whom received a placebo. People in the study were evaluated based on how well treatment improved their ability to read lines on an eye chart.

About 128 million Americans have presbyopia, AbbVie said, mostly in middle age or older.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

07-26-21 0633ET

All news about ABBVIE INC.
09/21INCYTE : FDA approves Incyte's eczema cream with boxed warnings
RE
09/20ABBVIE : Seeks FDA Approval for Crohn's Disease Treatment Candidate
MT
09/20ABBVIE : Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI«) for the Tr..
PR
09/20AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI«) for the T..
CI
09/16ABBVIE : Files Regulatory Applications in US and Europe for Upadacitinib to Treat Adults W..
MT
09/16ABBVIE : Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ«) for the..
PR
09/16AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib for the Treatmen..
CI
09/16AbbVie Submits Regulatory Applications for Treatment of Ulcerative Colitis
DJ
09/15China's biotech sector comes of age with big licensing deals, global ambitions
RE
09/14ABBVIE : and REGENXBIO Announce Eye Care Collaboration
AQ
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Financials (USD)
Sales 2021 56 247 M - -
Net income 2021 12 652 M - -
Net Debt 2021 66 393 M - -
P/E ratio 2021 14,6x
Yield 2021 4,78%
Capitalization 189 B 189 B -
EV / Sales 2021 4,55x
EV / Sales 2022 4,07x
Nbr of Employees 48 000
Free-Float 98,0%
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | ABBV | US00287Y1091 | MarketScreener
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 107,15 $
Average target price 125,48 $
Spread / Average Target 17,1%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman-Management Board & President
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.0.00%189 353
JOHNSON & JOHNSON4.54%431 227
ROCHE HOLDING AG10.52%321 941
PFIZER, INC.20.08%247 816
NOVO NORDISK A/S48.69%229 255
ELI LILLY AND COMPANY36.32%210 000